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Summary: By pooling SMART/START data, we found that a randomized strategy of 
interrupted/deferred ART increases the hazard of AIDS by 3.6, SNA by 1.6, and the 
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Abstract:   
Background: Pooled data from SMART and START were used to compare 
deferred/intermittent versus immediate/continuous antiretroviral therapy (ART) on disease 
risk.      
Methods: Endpoints assessed were AIDS, serious non-AIDS (SNA), cardiovascular 
disease (CVD), cancer, and death. Pooled (stratified by study) hazard ratios (HRs) from 
Cox models were obtained for deferred/intermittent ART vs immediate/continuous ART;  
analyses were conducted to assess consistency of HRs across baseline-defined 
subgroups. 
Results: Among 10156 participants, there were 124 AIDS, 247 SNA, 117 cancers, 103 
CVD and 120 deaths. Interventions in each trial led to similar differences in CD4 count and 
viral suppression Pooled HRs (95% CI) of deferred/intermittent ART vs 
immediate/continuous ART were for AIDS 3.63 (2.37, 5.56); SNA 1.62 (1.25-2.09); CVD 
1.59 (1.07-2.37); cancer 1.93 (1.32-2.83); and death 1.80 (1.24-2.61).  Underlying risk was 
greater in SMART than START.  Given the similar HRs for each study, absolute risk 
differences between treatment groups were greater in SMART than START. Pooled HRs 
were similar across subgroups.   
Conclusions: Treatment group differences in CD4 count and viral suppression were 
similar in SMART and START.  Likely as a consequence, relative differences in risk of 
AIDS and SNA between immediate/continuous ART and deferred/intermittent ART were 
similar. 
Key words: antiretroviral therapy, AIDS, cardiovascular disease, cancer, HIV 
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    The Strategies for Management of Antiretroviral Therapy (SMART) [1] and Strategic 
Timing of AntiRetroviral Treatment (START) [2] studies were the seminal trials to assess 
the effect of antiretroviral therapy (ART) treatment strategies on risk of both AIDS- and 
non-AIDS-defining events. These two studies, together with other trials [3,4], established 
continuous/immediate ART as the standard of care for HIV+ persons.  
    SMART and START were halted prematurely, by the respective data safety monitoring 
boards for each trial, before the target numbers of primary endpoints were reached. 
Therefore, each trial had a limited ability to quantify variation in risk of some outcomes 
such as cardiovascular disease (CVD) and cancer. To address this, we conducted a 
pooled analysis of the two trials in which we compared the drug conservation arm in 
SMART and the deferred ART arm in START(the “deferred/intermittent ART group”) with 
the viral suppression arm in SMART and the immediate ART arm in START (the 
“immediate/continuous ART group”). We hypothesized that treatment hazard ratios would 
be similar in each study and that the pooled analysis would better quantify the relative 
difference between interrupted/deferred ART and continuous/immediate ART  on risk of 
AIDS- and non-AIDS-defining events. 
Methods 
    SMART (NCT00027352) was a randomized controlled trial of 5,472 HIV+ persons with 
CD4+ > 350 cells/µL at baseline that compared continuous use of ART (viral suppression 
arm-VS) with structured treatment interruptions until the CD4+ cell count declined to less 
than 250 cells/µL (drug conservation arm-DC) [1] (Figure 1).  Recruitment occurred from 
January 2002 to January 2006, and the study was unblinded in January 2006 before the 
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planned enrolment was achieved.  START (NCT00867048) was a randomized trial of  
4,684 HIV+ ART naive persons with CD4+ > 500 cells/µL at baseline that compared 
immediate ART initiation (immediate ART arm-IMM) with deferred ART initiation until CD4+ 
cell counts dropped below 350 cells/µL or development of AIDS (deferred ART arm-DEF) 
[2] (Figure 1). The study enrolled from April 2009 to December 2013 and was unblinded in 
May 2015.   
    SMART and START were conducted in compliance with the Declaration of Helsinki 
Guidelines, were registered on clinical trial databases and reviewed by independent data 
and safety interim monitoring boards. An institutional review board/ethics committee at 
each study site approved the study protocol, and written informed consent was obtained 
from all participants. 
    A design schematic for the comparison of the “deferred/intermittent ART group” with the 
“immediate/continuous ART group” is illustrated in Figure 1. Follow-up was censored at 
the last known alive date or study unblinding (11 January 2006 for SMART and 25 May 
2015 for START), whichever occurred first. Definitions of AIDS and serious non-AIDS 
(SNA) were harmonized in SMART and START to match those in START [2,5]. Individual 
events comprising these composite outcomes were defined similarly [6-8]. The adjudicated 
clinical outcomes considered in this report were: a) AIDS or AIDS death; b) serious non-
AIDS (SNA) including CVD, non-AIDS cancer, end stage renal disease, decompensated 
liver disease and non-AIDS death; c) CVD including myocardial infarction, stroke, coronary 
revascularization and CVD death; d) AIDS and non-AIDS, infection-related and -unrelated 
cancer and cancer death; and e) all-cause death. Causes of death were coded using 
CoDe [9]. Cancer classification as infection-related or infection-unrelated was on the basis 
of individual review of case report forms and source documentation. Infection-related 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy442/5055761
by Consolidation Plus QUEEN user












cancer was defined as cancer driven by the following infectious agents: human 
herpesvirus 8 (HHV-8) (Kaposi sarcoma), Epstein-Barr virus (EBV) (non-Hodgkin 
lymphoma, Hodgkin lymphoma), human papilloma virus (HPV) (anal cancer, cervical 
cancer) [10-12]. All other malignancies were classified as infection-unrelated cancer.  
    Hazards ratios (HRs) for deferred/intermittent ART vs immediate/continuous ART were 
obtained from Cox models with a single indicator for treatment group for each trial 
separately.  Pooled HRs were estimated from Cox models, stratified by study (SMART vs. 
START), that included a single indicator variable for deferred/intermittent ART vs 
immediate/continuous ART.  Heterogeneity of HRs between SMART and START were 
assessed from models that included an interaction term between the pooled treatment 
group (deferred/intermittent ART vs immediate/continuous ART) and an indicator for study.  
HRs for deferred/intermittent ART vs immediate/continuous ART  were estimated for each 
cancer grouping (infection-related or infection-unrelated) in a Cox model that considered 
multiple events per participant [13].    To assess consistency of results across baseline-
defined subgroups defined by age, gender, race, CD4+ count, CD4:CD8 ratio, income 
region, smoking status, body mass index, hepatitis B/C co-infection, D-dimer, and IL-6 
levels, expanded Cox models that included interaction terms for the baseline subgrouping 
variable and the pooled treatment indicator were used.  
 In the analyses that compare HRs for SMART and START and in the subgroup 
analyses of the pooled HRs by baseline subgroups, the interaction p-values should be 
viewed cautiously.  Multiple endpoints are considered in the comparisons of SMART with 
START and multiple baseline subgroups were considered for the pooled HR.  This 
increases the risk of a type 1 error.  Also, the interaction test lacks power, and for many 
outcomes the number of events is small so there is a risk of a type 2 error.  
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    Changes in CD4 cell count from baseline through follow-up between the 
deferred/intermittent ART and immediate/continuous ART  groups (within each trial and 
pooled) were compared using longitudinal mixed models with random intercepts.  Viral 
suppression, defined as HIV RNA ≤ 400 copies/mL, was plotted over time, and the percent 
of follow-up time with viral suppression was estimated   
       Analyses were performed with SAS, version 9.3 (SAS Institute, Cary, NC).  P-values 
are 2-sided and values ≤0.05 were considered significant.  No adjustments were made for 
multiple comparisons.   
 
Results 
   10,156 participants, 4,684 from START and 5,472 from SMART,  were included (median 
age 40y; 27% female; 51% MSM; median baseline CD4+ 634 cells/µL; 37% smokers) 
(Table 1). Except for gender distribution, SMART and START participants differed 
markedly in terms of demographics, HIV-specific variables, hepatitis co-infection, smoking 
and ART (Table 1). Median nadir CD4+ count was 250 cells/µL in SMART and 553 cells/µL 
in START. SMART participants were also older and the majority (84%) were receiving 
ART at baseline (Table 1).  Median (interquartile range) follow-up was 1.0 (0.4, 2.1) years 
in SMART and 3.0 (2.2, 4.1) years in START.  
     During follow-up, the mean (95% CI) CD4+ cell count was 194 (187-200) cells/µL higher 
in the immediate/continuous ART group than the deferred/intermittent ART group (Figure 
2). The average CD4+ count difference between treatment groups in SMART and START 
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were identical, each was194 cells/µL  The treatment differences in CD4 counts between 
deferred/intermittent ART group and immediate/continuous ART group became clear 8 
months after randomization and remained so throughout follow up (Figure 2).  
    Compared to the deferred/intermittent ART group, the immediate/continuous ART group 
had a great proportion of participants with an HIV RNA level ≤ 400 copies/mL for more of 
the follow up period (Figure 3). The percent of follow-up time spent with a viral load < 400 
copies/mL was 84.2% in the immediate/continuous ART group compared to 33.3% in the 
deferred/intermittent ART group.  Similar differences were seen in each study (30.6% vs. 
89.2% in the DEF vs IMM arms of START; 38.7% vs. 74.1% in the DC vs. VS arms of 
SMART). 
    During 22,103 person-years of follow up, there were 124 AIDS events (fatal or non-
fatal), 247 SNA or non-AIDS deaths, and 363 AIDS, SNA or death events.  Pooled HRs 
(95% CI) of deferred/intermittent ART group vs immediate/continuous ART group were 
3.63 (2.37-5.56) for AIDS, 1.62 (1.25-2.09) for SNA, and 2.06 (1.65-2.56) for the 
composite of AIDS, SNA or death (Figure 4).  The SMART and START HRs for these 
outcomes were very similar, 3.63 and 3.62 for AIDS (p=0.99 for interaction), 1.74 and 1.56 
for SNA (p=0.71), and 2.40 and 1.87 (p=0.28) for the composite of AIDS, SNA or death.  
    For both AIDS and SNA, event rates were much higher in SMART than START.  
Coupled with the similar HRs, that resulted in absolute risk differences much larger for 
SMART than START (0.92 versus 0.50 per 100 person years for AIDS and 1.03 versus 
0.28 per 100 person years for SNA).  There is greater heterogeneity between the SMART 
and START HRs for CVD and cancer (p-values for interaction are 0.37 and 0.046, 
respectively).  In both trials, the pooled HRs are significantly greater than 1.0:  1.59 (1.07-
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2.37) for CVD and 1.93 (1.32-2.83) for cancer. The pooled HR for death was 1.79 (1.24-
2.61). 
   The HR (95%CI) of deferred/intermittent ART group vs immediate/continuous ART group 
for infection-related cancer was 2.3 (1.3-4.3), p=0.006, compared to 1.7 (1.0-2.8), p=0.04, 
for infection-unrelated cancer.  P-value comparing the HRs for infection-related versus 
infection-unrelated cancer was 0.43.  
 
       .  
Discussion  
    We pooled data from two landmark global HIV trials and found that a randomized 
strategy consisting of deferred/intermittent ART, increases the hazard of AIDS by 3.6, SNA 
by 1.6, and for the composite outcome of AIDS, SNA or death by 2.1 compared to 
immediate/continuous ART. Pooled treatment differences were similar across the 
subgroups investigated. The present study is the best randomized evidence that a strategy 
of deferred/intermittent ARTleads to an increased risk of AIDS-defining and serious non-
AIDS-defining conditions.  
    Compared with START participants, SMART participants were older, had lower nadir 
CD4 counts, lower follow-up CD4+ counts, and had been diagnosed with HIV for a much 
longer period of time.  As a consequence of these and other, as yet unknown differences, 
event rates were much higher in SMART as compared to START.  The similar relative 
differences in risk for the two studies coupled with the higher event in SMART resulted in 
much greater absolute risk differences in SMART compared to SMART.   
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    Our findings indicate that the relative vulnerability to develop immunodeficiency-related 
phenotypes is not affected by the degree of prior immunodeficiency. It appears that the 
relative effect of ART on disease risk is determined by the same factors irrespective of 
when ART is initiated. Interventions in SMART and START led to similar differences in 
CD4+ cell count and viral suppression, and these differences likely led to the similar HRs 
for the two studies. With respect to CD4+ cell counts, shifting the distribution from a mean 
of about 650 to 450 cells/µL during follow-up had the same impact on relative risk of AIDS 
and SNA as shifting it from 850 to 650 cells/µL (Figure 2).  
     Differences between SMART and START regarding cardiovascular outcomes have 
attracted interest from HIV researchers [14,15]. ART interruptions in SMART led to a 70% 
increased CVD risk [1]; whereas in START no significant differences in CVD risk [2] or 
surrogate markers of atherosclerosis [16,17] were observed.  Hunt et al hypothesized that 
the much lower nadir CD4+ counts of SMART participants, resulting from later ART 
initiation, were associated with a deeper perturbation of inflammatory-related pathways 
which, in turn, could drive a spectrum of end-organ diseases and cancers differently from 
that observed among START participants with higher nadir CD4+ counts [14]. It is also 
possible, as the p-value for interaction suggests, that the difference in HRs between the 
two trials for CVD is due to chance. 
    We have observed that the increased CVD risk for the deferred/intermittent ART group 
compared to the immediate/continuous ART group was consistent, without evidence of 
heterogeneity between SMART and START, despite a difference in nadir CD4+ counts of 
300 cells/µL.  However, observed HRs for CVD were numerically different in each trial 
(1.18 for START versus 1.77 in SMART).  Lower HRs for START may have reflected the 
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small number of CVD events and insufficient power to detect significant differences in risk. 
Follow up was short in START and participants had an inherent low cardiovascular risk at 
study entry. Efforts are underway to extend follow up among START participants until 
2021. This will allow us to determine with accuracy HRs for CVD events in the future. 
Higher levels of inflammation and coagulation markers measured at study entry were 
significantly associated with subsequent CVD risk both among SMART [18] and START 
participants [17]. The definition of CVD, as a part of the composite endpoint for each trial, 
was virtually the same. Hence, we believe that the variation in absolute CVD risk between 
SMART and START likely reflects differences in prevalent risk factors between the two 
study populations. For instance, SMART participants were older, had a higher prevalence 
of traditional CVD risk factors and received more toxic and old-fashioned ART regimens 
than START participants.  
    The impact of continuous ART in SMART [19] and immediate ART in START [12] in 
reducing the risk of infection-related cancer was significant and comparable between the 
two studies.  As for infection-unrelated cancer, it remained unclear whether the non-
significant reduction in risk in both studies [12,19] reflected limited power. The present 
pooled analysis combining START and SMART had enough statistical power to better 
estimate the impact of ART strategies on the risk of infection-unrelated cancer than each 
study separately. The significant increase in risk associated with deferred/intermittent ART 
did not vary by type of cancer, and was consistently observed for infection-related and -
unrelated cancer (P=0.43).  
    In a previous report, we showed that the benefit of ART in reducing cancer risk was not 
entirely attributable to HIV RNA suppression [12]. Possible mediators of ART benefit could 
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have been a curb on oncogenic virus coinfection and/or reduction of inflammation [12,20]. 
Enhanced inflammation and coagulation, as demonstrated by higher levels of IL-6 and D-
dimer, was associated with higher risk of cancer (both infection-related and -unrelated) 
among SMART participants [11]. In START, however, these biomarkers did not predict 
cancer risk [18]. The interplay between ART, inflammation and cancer risk is therefore 
complex; further research is needed to identify mediators of the benefit of 
immediate/continuous ART in reducing cancer risk. 
    Our study has limitations to be acknowledged. First, SMART and START were distinct 
clinical experiments testing different ART strategies in study populations with dissimilar 
underlying risk profiles. Still, a pooled analysis of SMART and START seemed to us 
justified given the similar outcomes in deferred/intermittent ART vs immediate/continuous 
ART (Figure 4) and the larger number of individual endpoints for a better risk estimation. 
Second, the number of rare but very clinically relevant outcomes such as end-stage renal 
and liver diseases was too small to allow risk estimation. As a result, these heterogeneous 
outcomes had to be combined as SNA. With respect to cancer and CVD, however, our 
analyses had more power. Third, START recruited participants from low-resource settings 
with limited the diagnostic capacity. It is possible that some outcomes, such as myocardial 
infarction, might have been under-diagnosed. Fourth, we did not present pooled data on 
ART-related complications because events were collected differently in each trial. In 
SMART, there were more grade 4 events in DC than VS arm (173 vs 148; p=0.13).  
Similarly, there were more events for a composite of grade 4 or death in DC than VS a 
(205 vs 164; p=0.03) [1].  In START, we collected and reported grade 4 events and 
unscheduled hospitalizations as separate item [2,5].  Like SMART, there were fewer of 
these events in the immediate ART arm.  For the composite of grade 4, unscheduled 
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hospitalization or death there 283 participants with at least one event in the immediate 
group and 311 in the deferred group (p=0.25). On the basis of these results, one can infer 
that no increased toxicity should be expected from immediate/continuous ART compared 
to deferred/intermittent ART. 
 
     To conclude, compared to a strategy of immediate/continuous ART, a strategy of 
deferred/intermittent ART, increased the risk of AIDS and SNA events among HIV+ 
persons consistently in SMART and START. Interventions in SMART and START led to 
similar absolute differences in mean CD4+ cell count and percentage with viral 
suppression which in turn led to similar relative risk estimates for AIDS and SNA in each 
study.  Pooled treatment differences for the composite outcome of AIDS, SNA, or death 
were similar across a number of subgroups.  
 
Acknowledgments 
    This study was funded by NIH [grant numbers: U01AI068641, U01AI042170 and 
U01AI46362 (SMART); UM1-AI068641 and UM1-AI120197 (START)]. START was 
supported by the National Institute of Allergy and Infectious Diseases (United States), 
Agence Nationale de Recherches sur le SIDA et les Hipatites Virales (France), National 
Health and Medical Research Council (Australia), Danish National Research Foundation 
(Denmark), Bundes ministerium für Bildung und Forschung (Germany), European AIDS 
Treatment Network,Medical Research Council (United Kingdom), National Institute for 
Health Research, National Health Service (United Kingdom), and the University of 
Minnesota. Antiretroviral drugs were donated to the central drug repository by AbbVie, 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy442/5055761
by Consolidation Plus QUEEN user












Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen 
Scientific Affairs, and Merck. 
    The present study was also supported by the Research Council at Rigshospitalet and by 
the Danish National Research Foundation (grant DNRF126). AHB is supported by 
Lundbeckfonden (R219-2016-762).  
    The funders had no role in study design, data collection and analysis, decision to 
publish, or preparation of this manuscript. 
    We would like to thank the SMART and START investigators and participants. See N 
Engl J Med 2006; 355:2283-96 for the complete list of SMART investigators and N Engl J 
Med 2015; 373:795-807 (supplementary material) for the complete list of START 
investigators.   
    AHB, JN, SS, JDN and JDL conceived the study. JN and SS performed the statistical 
analyses. AHB drafted the manuscript. All authors contributed to data interpretation, 
critically revised the manuscript and approved the final version. 
    This study was presented in part at the 24th Conference on Retroviruses and 
Opportunistic Infections, 13-16 February 2017, Seattle. Abstract 474 
Conflicts of interest  
The authors have no conflicts of interest to declare.  
 
List of Tables and Figures 
Table1: Baseline characteristics 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy442/5055761
by Consolidation Plus QUEEN user













Figure 1: Study Design 
ART=antiretroviral therapy; DC: drug conservation; DEF=deferred; deferred/intermittent 
ART group; IMM=immediate; immediate/continuous ART group; SMART: Strategies for 
Management of Antiretroviral Therapy; START=Strategic Timing of Antiretroviral 
Treatment; VS=viral suppression 
 
Figure 2: Mean CD4 cell counts over follow-up by treatment group for START, SMART, 
and the pooled deferred/intermittent and immediate/continuous ART groups.   
 
Figure 2 legend: The vertical lines around the data points represent the 95% confidence 
interval (CI). Figure is truncated at 48 months. The table within the figure presents the 
mean CD4 cell count difference (with 95% CI) over follow-up between the immediate and 
deferred groups in START, the viral suppression and drug conservation groups in SMART, 
and the pooled immediate/continuous and deferred/intermittent ART groups.   
DC: drug conservation; DEF=deferred; deferred/intermittent ART group; IMM=immediate; 
immediate/continuous ART group; SMART: Strategies for Management of Antiretroviral 
Therapy; START=Strategic Timing of Antiretroviral Treatment; VS=viral suppression 
 
Figure 3: Percent of participants with HIV RNA ≤ 400 copies/mL over follow-up, by 
treatment group for START, SMART, and the pooled deferred/intermittent and 
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immediate/continuous ART groups. Figure 3 Legend: Figure is truncated at 48 months. 
DC: drug conservation; DEF=deferred; IMM=immediate; immediate/continuous ART 
group; START=Strategic Timing of Antiretroviral Treatment; VS=viral suppression 
 
Figure 4: HRs (95% CI) comparing event risk by treatment group within START and 
SMART separately, and between the pooled deferred/intermittent and 
immediate/continuous ART groups.  
Figure 4 legend: The p-value for interaction is comparing the HR for each event between 
the deferred vs. immediate group within START to the HR for the same event between the 
viral suppression vs. drug conservation group within SMART.    
CI: confidence interval, CVD: cardiovascular disease; HR: hazard ratio; SMART: 
Strategies for Management of Antiretroviral Therapy; SNA: serious non-AIDS; 
START=Strategic Timing of Antiretroviral Treatment 
 
 Figure 5: Subgroup analyses for the composite endpoint of AIDS, SNA or death events; 
HRs (95% CI) comparing the deferred/intermittent ART group vs. immediate/continuous 
ART group within the pooled cohort. 
Figure 5 Legend: For subgroups of age, CD4 cell count, CD4:CD8 ratio, body mass index, 
D-dimer, and IL-6, the continuous variables were used for the interaction tests.  .  Baseline 
CD4:CD8 ratio, hepatitis B/C co-infection, D-dimer and IL-6 were not available for all 
participants; HRs within subgroups for these measures were computed using participants 
with available baseline data.   
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CI: confidence interval, HR: hazard ratio; deferred/intermittent ART group; 
immediate/continuous ART group 
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Median age (IQR) 36 (29 - 44) 43 (38 - 50) <0.001 40 (33 - 48)  
Female (%) 26.8 27.2 0.72 27.0  
Race or ethnic group (%)         
Black 30.1 29.1   29.6  
Latino or Hispanic 13.6 21.1   17.6  
Asian 8.3 4.1   6.0  
White 44.6 43.6   44.0  
Other 3.5 2.1   2.8  
Geographical region (%)         
Africa 21.3 1.2   10.5  
Asia 7.6 3.2   5.2  
Australia 2.3 3.2   2.8  
Europe 32.9 25.8   29.1  
North America 10.8 56.5   35.4  
Latin America 25.1 10.0   17.0  
% from high income country 46.0 85.6  67.3  
Median years since HIV diagnosis (IQR) 1 (0 - 3) 8 (5 - 12) <0.001 4 (1 - 9)  
Median CD4 (IQR) 651 (584 - 765) 597 (466 - 790) <0.001 634 (539 - 776)  
Median CD4:CD8 ratio (IQR)** 0.66 (0.48 - 0.89) 0.69 (0.48 - 0.97) <0.001 0.67 (0.48 - 0.93)  
Median nadir CD4 (IQR) 553 (488 - 654) 250 (154 - 358) <0.001 418 (237 - 558)  
Median HIV RNA (IQR)** 12761 (3025 - 43482) 80 (50 - 793) <0.001 1568 (50 - 19274)  
HIV RNA ≤ 400 copies/mL (%) 7.9 71.7  42.3  
On ART at baseline (%) 0.0 84.0  45.2  
ART naive (%) 100.0 4.6  48.6  
Hepatitis coinfection (%)** 6.4 17.0 <0.001 12.2  
Current smoker (%) 32.0 40.5 <0.001 36.6  
Median BMI (IQR)** 24.6 (22.1 - 27.9) 24.9 (22.4 - 28.1) <0.001 24.8 (22.3 - 28.0)  
Median IL-6 (IQR)** 1.39 (0.97 - 2.12) 1.77 (1.09 - 3.01) <0.001 1.57 (1.03 - 2.57)  
Median D-dimer (IQR)** 0.33 (0.23 - 0.50) 0.22 (0.13 - 0.38) <0.001 0.27 (0.17 - 0.45)  
*p-value comparing SMART and START for selected baseline characteristics that did not reflect differences due to 
study design/conduct. Chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables 
**Missing baseline data for the following: CD4/CD8 ratio – START=56, SMART=2637; HIV RNA – START=9, 
SMART=15; hepatitis B/C coinfection – START=54, SMART=8; BMI – SMART=21; IL-6 – START=388, SMART=435; 
D-dimer – START=410, SMART=403. 
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ART= antiretroviral therapy; BMI=body mass index; IQR=interquartile range; SMART: Strategies for Management of 
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